Continued from page 1

The Reproductive Health Technologies Project criticized the FDA’s decision last week to grant exclusive marketing rights to Teva for three years. As a result, other drug makers cannot sell a generic version of the pill to customers younger than 17 without a prescription until the exclusivity period ends.

“It’s just another symptom of all of the problems we’ve seen with bringing emergency contraception over-the-counter,” RHTP President and CEO Jessica Arons said.

Teva declined to comment on the FDA’s decision.

Ms. Arons and other advocates for birth-control access said a hodgepodge of rules for Plan B One-Step versus other morning-after pills could cause confusion.

“Obviously, this regime continues to perpetuate confusion and the age restriction was never supported by the scientific evidence and only enacted for political reasons,” said Andrea Costello, an attorney for the Partnership for Civil Justice Fund, which helped to litigate the Plan B case.